SGEN - Seattle Genetics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
74.01
+1.23 (+1.69%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close72.78
Open73.15
Bid73.93 x 800
Ask73.98 x 1000
Day's Range72.70 - 74.39
52 Week Range50.71 - 84.37
Volume1,479,263
Avg. Volume980,548
Market Cap11.969B
Beta (3Y Monthly)1.74
PE Ratio (TTM)N/A
EPS (TTM)-1.74
Earnings DateOct 23, 2019 - Oct 28, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est80.43
Trade prices are not sourced from all markets
  • The Seattle Genetics (NASDAQ:SGEN) Share Price Has Gained 76% And Shareholders Are Hoping For More
    Simply Wall St.

    The Seattle Genetics (NASDAQ:SGEN) Share Price Has Gained 76% And Shareholders Are Hoping For More

    Stock pickers are generally looking for stocks that will outperform the broader market. Buying under-rated businesses...

  • Seattle Genetics' Enfortumab Vedotin BLA Gets Priority Review
    Zacks

    Seattle Genetics' Enfortumab Vedotin BLA Gets Priority Review

    The FDA accepts Seattle Genetics (SGEN) and Astellas' BLA for enfortumab vedotin under a priority review to treat advanced/metastatic urothelial cancer. A verdict is pending on Mar 15, 2020.

  • Business Wire

    Seattle Genetics Announces Presentations of New Clinical Data from Multiple Studies of Novel Targeted Therapies at the European Society for Medical Oncology (ESMO) 2019 Congress

    – First Presentation of Initial Data from a Phase 1 Trial of Enfortumab Vedotin Plus Pembrolizumab in Locally Advanced or Metastatic Urothelial Cancer Featured in an Oral Session –

  • Seattle Genetics and Astellas Announce U.S. FDA Grants Priority Review for Enfortumab Vedotin Biologics License Application in Locally Advanced or Metastatic Urothelial Cancer
    PR Newswire

    Seattle Genetics and Astellas Announce U.S. FDA Grants Priority Review for Enfortumab Vedotin Biologics License Application in Locally Advanced or Metastatic Urothelial Cancer

    BOTHELL, Wash. and TOKYO, Sept. 16, 2019 /PRNewswire/ -- Seattle Genetics, Inc. (SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced that the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for the investigational agent enfortumab vedotin and granted Priority Review for the treatment of patients with locally advanced or metastatic urothelial cancer who have received a PD-1/L1 inhibitor and who have received a platinum-containing chemotherapy in the neoadjuvant/adjuvant, locally advanced or metastatic setting. The filing is based on results from the first cohort of patients in the EV-201 pivotal phase 2 clinical trial that were presented as a late-breaking oral presentation at the annual meeting of the American Society of Clinical Oncology (ASCO) in June 2019.

  • Benzinga

    Oppenheimer Turns Bullish On Seattle Genetics, Says Optimism Fueled By Pipeline Readouts

    While recent pullback in Seattle Genetics, Inc’s (NASDAQ: SGEN ) shares presents an attractive entry point, there are several pipeline catalysts ahead, according to Oppenheimer. The Analyst Oppenheimer’s ...

  • GuruFocus.com

    Seattle Genetics Inc (SGEN) President and CEO Clay B Siegall Sold $1.9 million of Shares

    President and CEO of Seattle Genetics Inc (30-Year Financial, Insider Trades) Clay B Siegall (insider trades) sold 28,472 shares of SGEN on 09/09/2019 at an average price of $68.33 a share. Continue reading...

  • Benzinga

    The Week Ahead In Biotech: Conference Presentations, IPO News Flow Take The Spotlight

    The holiday-shortened week saw a few huge moves by individual stocks. Abeona Therapeutics Inc (NASDAQ: ABEO ) was among the biggest gainers after the biopharma announced plans to explore strategic alternatives. ...

  • GuruFocus.com

    Seattle Genetics Inc (SGEN) President and CEO Clay B Siegall Sold $2.1 million of Shares

    President and CEO of Seattle Genetics Inc (30-Year Financial, Insider Trades) Clay B Siegall (insider trades) sold 28,951 shares of SGEN on 08/28/2019 at an average price of $73.21 a share. Continue reading...

  • Therapeutics startup raises $65M in latest round to fight kidney disease
    American City Business Journals

    Therapeutics startup raises $65M in latest round to fight kidney disease

    Chinook Therapeutics is based in Vancouver, B.C., but its CEO lives and works in Seattle — and he's looking to for space in the city to support six to 12 additional employees.

  • GuruFocus.com

    Seattle Genetics Inc (SGEN) CFO Todd E Simpson Sold $1,000,000 of Shares

    CFO of Seattle Genetics Inc (30-Year Financial, Insider Trades) Todd E Simpson (insider trades) sold 12,500 shares of SGEN on 08/20/2019 at an average price of $80 a share. Continue reading...

  • Did Seattle Genetics, Inc. (NASDAQ:SGEN) Insiders Sell Shares?
    Simply Wall St.

    Did Seattle Genetics, Inc. (NASDAQ:SGEN) Insiders Sell Shares?

    It is not uncommon to see companies perform well in the years after insiders buy shares. Unfortunately, there are also...

  • Alder on hiring binge ahead of FDA ruling
    American City Business Journals

    Alder on hiring binge ahead of FDA ruling

    Leading up to the anticipated February 2020 FDA approval date, Alder plans to double the size of its workforce.

  • Why Is Seattle Genetics (SGEN) Up 2.4% Since Last Earnings Report?
    Zacks

    Why Is Seattle Genetics (SGEN) Up 2.4% Since Last Earnings Report?

    Seattle Genetics (SGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • GuruFocus.com

    Seattle Genetics Inc (SGEN) President and CEO Clay B Siegall Sold $1.5 million of Shares

    President and CEO of Seattle Genetics Inc (30-Year Financial, Insider Trades) Clay B Siegall (insider trades) sold 20,149 shares of SGEN on 08/08/2019 at an average price of $76.52 a share. Continue reading...

  • Top Biotech Stocks for February 2019
    Investopedia

    Top Biotech Stocks for February 2019

    Biotech a thrilling industry for investors, and one with tremendous opportunity for gains, as shown in early 2019, but it is notably risky for investors, too.

  • Benzinga

    Jim Cramer Weighs In On Berkshire Hathaway, Range Resources, Zynerba And More

    On Monday's “Mad Money,” Jim Cramer said he remains bearish on Range Resources Corp. (NYSE: RRC ) saying natural gas is the weakest part of the petrol chain. Cramer says although it's speculative, he is ...

  • Seattle Genetics Has a Rally in Its DNA
    TheStreet.com

    Seattle Genetics Has a Rally in Its DNA

    A caller to Mad Money Monday night asked about Seattle Genetics Inc. : "I have faith in them. In the daily bar chart of SGEN, below, we can see that prices have been stuck in a sideways trading range with lower highs seen in October, April and probably July. Despite the sideways movement of prices the daily On-Balance-Volume (OBV) line shows a decline from early February to the middle of July which tells us that sellers of SGEN have been more aggressive.

  • 3 “Perfect 10” Biotech Stocks to Buy
    TipRanks

    3 “Perfect 10” Biotech Stocks to Buy

    When looking for compelling stocks with significant long-term growth potential, investors will often turn to biotechs. A biotech is any company that uses technology involving living organisms to create medical or agricultural products. The S&P Biotechnology Select Industry Index, the biotech section of the index, gained 18% over the last ten years. Many analysts and financial bloggers believe that this trend will persist. But how do investors know which biotech stocks are ready to grow?As investors, we look at a combination of factors rather than a single metric to make the most informed decisions. These factors can include analyst ratings, insider activity, news sentiment and financial blogger opinions. The Smart Score metric weighs these factors and combines them into a single numerical score with 10 being the highest.Here are 3 biotech stocks that scored a “Perfect 10”. Gilead Sciences, Inc. (GILD)GILD researches, develops and commercializes antiviral drugs primarily used for the treatment of HIV, hepatitis B, hepatitis C and influenza. The company will report its Q2 2019 earnings on July 30. According to recent consensus estimates, it is expected to see a 2% dip in revenue from the prior-year quarter to $5.5 billion. EPS is expected to be $6.90, up 4% year-over-year. While the revenue projection is worrisome, the company has made significant efforts to pull off a turnaround.On March 28, Gilead and its partner, Galapagos NV (GLPG), announced positive results from its phase 3 clinical study testing its filgotinib drug to treat rheumatoid arthritis. The study demonstrated the drug’s improved efficacy when compared to other treatment options. The company announced on July 15 that it will invest $5.1 billion to increase its stake in Galapagos. This will allow both companies to research and bring new treatments to the market over the next ten years. The company also announced on July 19 that it would be licensing three preclinical programs from its competitor, Novartis AG (NVS). The deal gives GILD exclusive rights to develop and create commercial treatments using several small molecules that have the potential to treat human rhinovirus, influenza and herpes. As per the terms of the agreement, NVS received an upfront payment for an undisclosed amount, and will potentially get an additional $291 million in milestone payments and royalties on annual net sales. Top financial blogger, Josh Enomoto writes, “If nothing else, GILD belongs on your list of stocks to buy thanks to its cash position. Even under a challenging environment, Gilead managed nearly $12 billion in operating cash flow last year. The company is more than stable enough to continue supporting its dividend yield, which currently stands at 3.68%.”Five-star analyst from Wells Fargo, Jim Birchenough, agrees that investors should still pick GILD. On July 15, he upgraded the stock to a Buy and raised his price target from $68 to $88, suggesting 35% upside. “We expect GILD earnings growth to reaccelerate beyond 2020 on continued HIV product growth and on incremental contribution from Galapagos-Partnership programs in fibrosis and inflammation,” he said. The analyst has a 22% average return per rating. The Street is cautiously optimistic on GILD. The “Perfect 10” stock has a ‘Moderate Buy’ analyst consensus and an $81 average price target, indicating 25% upside potential. It also boasts bullish financial blogger and news sentiment.   Seattle Genetics Inc. (SGEN)SGEN is the innovative biotech company known for using monoclonal antibody-based therapies to develop treatments for cancer. Share prices have soared 32% year-to-date, with the word on the Street being that there’s more growth to come. Based on the company’s July 16 earnings release, things are looking good. Its Q2 2019 revenue was up 28% year-over-year to $218 million from the prior-year quarter. Sales of Adcetris, the company’s lymphoma drug, increased 30% year-over-year in the U.S. and Canada. Management attributes this jump to the drug’s improved treatment of peripheral T-cell lymphoma and frontline Hodgkin lymphoma. Its full year guidance is forecasting $610 million to $640 in Adcetris sales. The company also saw royalty revenue surge by 13% year-over-year. At the beginning of July, SGEN announced it submitted a marketing application to the FDA for a new urothelial cancer treatment with its partner, Astellas Pharma. If the drug is approved, shares could rise even more. Piper Jaffray analyst, Joseph Catanzaro, agrees with that sentiment. On July 17, he upgraded the stock to a Buy and raised the price target from $64 to $75. “We believe Seattle Genetics' 2019 guidance of $610M-$640M is well within reach while it has the opportunity to report positive data from multiple potential registration trials over the next 12 months,” he said. Another top analyst, Kennen MacKay, maintained his Buy rating while raising the price target from $79 to $80, suggesting 7% upside. The RBC Capital analyst said on July 17, “The Adcetris beat adds commercial excitement to catalyst rich H2. We conservatively increase FY19 Adcetris sales estimates to the high end of FY19 guide ($610M-$640M) noting high probability of beat/raise in quarters ahead.” SGEN has a ‘Moderate Buy’ analyst consensus, with 6 Buy ratings vs 4 Holds received over the last three months. It has an average price target of $79, suggesting 4% upside. Financial bloggers and hedge funds are bullish the stock. Over the last quarter, hedge funds have increased their SGEN holdings by 113,000 shares. Vertex Pharmaceuticals Inc. (VRTX)The last “Perfect 10” on our list is dedicated to discovering new cystic fibrosis (CF) treatments. CF is a genetic disorder that primarily affects the lungs and causes difficulty breathing. While share prices have only increased 5% year-to-date, the company’s broad product pipeline inspires confidence.The company controls a majority of the cystic fibrosis market space, as its drugs treat the underlying causes of the genetic disease. VRTX believes that it has only reached half of the patients that could benefit from these treatments. Management believes they can expand their patient base by another 50% through additional treatments for younger patients. Not to mention VRTX stands to grow its reach even further. The company plans to file a triple-drug combo for FDA approval to help it access more of the market as well as develop therapies for other diseases. On June 7, VRTX announced that it entered into a definitive agreement worth $245 million to acquire all outstanding shares of gene editing therapies developer Exonics Therapeutics. Exonics’ technology will allow VRTX to offer treatments for other genetic diseases such as Duchenne Muscular Dystrophy (DMD).Ahead of its July 31 earnings release, the company is expected to deliver gains. According to consensus estimates, revenue could reach $884 billion, up 18% year-over-year. Quarterly EPS should also see an increase of 11%, reaching $1.04 per share. H.C. Wainwright analyst, Andrew Fein, is optimistic about this biotech. On July 22, he reiterated his Buy rating and price target of $220, suggesting 27% upside. He notes that while the company runs the risk of “failure in further combination clinical studies, failure to achieve peak sales revenue and product competition”, he maintains his bullish thesis. Top financial blogger, William Meyers writes, “In the past I have usually cautioned about its relatively high stock price and market capitalization compared to other large-cap biotechs, but its pipeline is broad and deep, which is a good sign for long-term investors,” he said. The Street is bullish on VRTX. The stock boasts a ‘Strong Buy’ analyst consensus and a $215 average price target, suggesting 23% upside. It also has a very bullish sentiment from news outlets, with positive technicals and fundamentals.

  • Thomson Reuters StreetEvents

    Edited Transcript of SGEN earnings conference call or presentation 16-Jul-19 8:30pm GMT

    Q2 2019 Seattle Genetics Inc Earnings Call

  • Seattle Genetics Hits Its Second Growth Phase
    Motley Fool

    Seattle Genetics Hits Its Second Growth Phase

    There's potential for more with a pipeline of drugs in development.

  • Why Seattle Genetics, AVROBIO, and First Majestic Silver Jumped Today
    Motley Fool

    Why Seattle Genetics, AVROBIO, and First Majestic Silver Jumped Today

    Despite declines in the broader market, good news lifted shares of these companies.